Pharmaceuticals US

US Hyperuricemia Drugs Market Analysis, 2024–2034

US Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.02 Bn Estimated value
Estimate 2025 $1.07 Bn 38.9% of the global market
Projected 2034 $1.70 Bn 59.2% Adds $633.2 Mn over 9 forecast years
CAGR 2025–2034 5.3% Faster than 42% of 180 Pharmaceuticals markets here
Key players 5
  • US is 38.95% of the global market.
  • In North America, the largest is US (this report) at $1.07 Bn.
  • Fastest growing: Canada at 7.1% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$633.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hyperuricemia Drugs Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.02 Bn — —
2025 (base) $1.07 Bn +$53.9 Mn —
2026 (forecast) $1.13 Bn +$56.7 Mn +5.3%
2027 (forecast) $1.19 Bn +$59.7 Mn +10.9%
2028 (forecast) $1.25 Bn +$62.9 Mn +16.8%
2029 (forecast) $1.32 Bn +$66.2 Mn +22.9%
2030 (forecast) $1.39 Bn +$69.7 Mn +29.5%
2031 (forecast) $1.46 Bn +$73.4 Mn +36.3%
2032 (forecast) $1.54 Bn +$77.3 Mn +43.5%
2033 (forecast) $1.62 Bn +$81.4 Mn +51.2%
2034 (forecast) $1.70 Bn +$85.7 Mn +59.2%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.75 Bn
  2. North America $1.53 Bn
  3. US (this report) $1.07 Bn
  4. APAC $635.4 Mn
  5. Europe $520.2 Mn
  6. Canada $223.6 Mn
  7. China $206.3 Mn
  8. Japan $178.6 Mn
  9. Middle East $126.4 Mn
  10. Latin America $122.7 Mn
  11. Germany $85.2 Mn
  12. UK $77.0 Mn
  13. Brazil $74.9 Mn
  14. France $65.5 Mn
  15. Italy $63.9 Mn
  16. India $59.6 Mn
  17. Ecuador $56.2 Mn
  18. Saudi Arabia $54.5 Mn
  19. Spain $48.6 Mn
  20. Africa $42.3 Mn
  21. Mexico $40.9 Mn
  22. Australia $37.3 Mn
  23. New Zealand $28.1 Mn
  24. Russia $26.8 Mn
  25. South Africa $20.7 Mn
  26. UAE $14.9 Mn
  27. Egypt $7.5 Mn
  28. Philippines $6.1 Mn
  29. Hong Kong $4.3 Mn
  30. Malaysia $3.9 Mn
  31. Singapore $3.2 Mn
  32. Thailand $3.0 Mn
  33. Kenya $1.6 Mn

The US Hyperuricemia Drugs Market Analysis Executive Summary

Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.

Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).

US Hyperuricemia Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Hyperuricemia Drugs Market in US

The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hyperuricemia Drugs Market in US

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.

Clinical trials

10 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Crystalys Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanton Pharma 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 2,548 papers since 2021 (worldwide)

  1. Curcumin-mediated antimicrobial photodynamic therapy attenuates MRSA skin infection in hyperuricemic mice. Free radical biology & medicine, 2026
  2. Neglected chronic tophaceous gout complicated by massive ulceration and destructive polyarticular arthropathy: a case report. Annals of medicine and surgery (2012), 2026
  3. Primary hyperoxaluria type 2 presenting with febuxostat-associated acute tubular injury in a kidney transplant recipient: a case report. Frontiers in immunology, 2026
  4. Fructose-1,6-bisphosphatase deficiency initially diagnosed as acute necrotizing encephalopathy in a child: a case report. BMC pediatrics, 2026
  5. Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges. Experimental and molecular pathology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hyperuricemia Drugs in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

Questions, answered with public data

How many clinical trials on Hyperuricemia Drugs are running in the US?
10 studies are recruiting, active or about to start in the US.[4]
How much research is published on Hyperuricemia Drugs?
PubMed lists 2,548 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Hyperuricemia Drugs in US? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in US

See all
Same topic, other categories

Related on kidney health

See the topic